Primary cellular protein degradation pathway. E1 activates ubiquitin (ATP-dependent thioester); E2 conjugating enzymes carry activated ubiquitin; E3 ligases (~600 in humans — APC/C, SCF, MDM2, VHL, RNF, etc.) determine substrate specificity. Substrate proteins receive K48-linked polyubiquitin chains → recognized by the 19S regulatory cap of the 26S proteasome → unfolding + threading + 20S core proteolysis → peptides. Distinct K63-linked ubiquitination signals trafficking + autophagy, not degradation. Pharmacology: BORTEZOMIB (Velcade) + CARFILZOMIB + IXAZOMIB = 26S proteasome inhibitors for multiple myeloma + mantle cell lymphoma (myeloma plasma cells are exquisitely dependent on protein turnover). Thalidomide / lenalidomide / pomalidomide bind cereblon → redirect CRBN E3 ligase to ubiquitinate IKZF1/3 (immunomodulatory mechanism for myeloma + MDS).
Organ Systems
immune-hematologic
nervous
Pathway Steps
substrate-protein → monoubiquitinated — via E1 → E2 → E3 ligase (substrate-specific). The cascade — activating E1, conjugating E2, substrate-specific E3 ligase — tags proteins, with the hundreds of E3 ligases providing specificity. This is the substrate of PROTAC/molecular-glue degraders and of MDM2 (p53) and VHL (HIF) ligase biology.
monoubiquitinated → polyubiquitinated-k48 — via chain elongation (E4 enzymes + processive E2-E3). K48-linked chains are the canonical degradation signal — distinct from K63 chains, which signal trafficking/DNA repair. Chain topology (the “ubiquitin code”), not merely the presence of ubiquitin, determines the substrate’s fate.
polyubiquitinated-k48 → proteasomal-peptides — via 26S proteasome — BORTEZOMIB / CARFILZOMIB target. The 26S proteasome unfolds and degrades tagged proteins (recycling ubiquitin) and is the bortezomib/carfilzomib target — multiple-myeloma cells, with huge immunoglobulin output, are especially dependent on proteasomal clearance of misfolded protein.
Known Modulators
withaferin a (inhibitor) — 26S proteasome (covalent — Mitogen-1/Y/RPN13 subunits). Cancer-context proteasome inhibition; preclinical synergy with bortezomib-class agents.